<DOC>
	<DOCNO>NCT01543113</DOCNO>
	<brief_summary>Background : Metastatic melanoma devastate prognosis one top cause cancer death young patient . Until , available therapy unreliable , recent understand melanoma ' molecular pathway improve classification new clinical strategy propose . Initial study show B-Raf/N-Ras mutation ( respectively V600E Q61 ) frequent alteration present 70 80 % melanoma , characterize non Chronic Sun-induced Damage skin ( CSD ) . These include Superficial Spreading Melanomas ( SSM ) Nodular Melanomas ( NM ) . Other study show c-Kit mutation presently predominant activate mutation ( 20 - 40 % ) Acro-Lentiginous Melanomas ( ALM ) , Mucous Melanomas ( MM ) melanomas arise CSD skin . c-Kit mutation pattern complex four exon affect lead different mutation , incidence biological impact less document . BRAF/NRAS genetics alteration drive constantly cell growth , thus attractive target . Spectacular result indeed obtain BRAF inhibitor target V600E BRAF-mutated form . Data GIST disease reveal different c-Kit mutation modulate differently c-Kit function response target therapy . Because c-Kit target therapy critical clinical issue , investigator aim identify frequent mutation present population propose appropriate screen test adapt therapy . Methods : 250 melanoma sample correspond homogeneous white-Caucasian population ( Brittany , France ) screen . c-Kit exon 11 , 13 , 17 18 sequence ( direct sequence pyrosequencing possible ) . c-Kit copy number quantify q-PCR level c-Kit determine immunohistochemistry ( IHC , CD117 ) . Samples also analyze B-Raf mutation codon 464 , 466 , 469 600 , N-Ras mutation codon 12 , 13 61 ( Pyrosequencing ) . Expected Results : Taken together , investigator anticipate present genetic analysis tumour patient advance melanoma first document type frequency cKit mutation , confirm BRAF , NRAS cKit mutation mutually exclusive document repartition melanomas sub-types . Finally study clue researcher well patient respond therapy target growth-promoting protein BRAF/NRAS cKIT .</brief_summary>
	<brief_title>cKIT , BRAF/NRAS Mutations Advanced Melanoma : Clinical Outcome Response Tyrosine-kinase Inhibitors - KitMel Project</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>melanoma white caucasian population</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>melanoma</keyword>
	<keyword>white-caucasian population</keyword>
</DOC>